Advertisement

Drugs & Therapy Perspectives

, Volume 35, Issue 1, pp 13–20 | Cite as

Erenumab in the prophylaxis of migraine: a profile of its use

  • Emma H. McCaffertyEmail author
  • Katherine A. Lyseng-Williamson
Adis Drug Q&A
  • 46 Downloads

Abstract

Erenumab (Aimovig®, erenumab-aooe), a fully human monoclonal antibody (MAb) calcitonin gene-related peptide (CGRP) receptor antagonist, is the first MAb approved for the prophylaxis of migraine in adults. Erenumab is subcutaneously administered and has a convenient once-monthly/every-4-week dosing regimen. In patients with episodic or chronic migraine, erenumab is effective and generally well tolerated, significantly reducing the frequency of migraines and the use of migraine-specific medications during weeks 9–12 and months 4–6 relative to placebo. Erenumab also displays efficacy in numerous subgroup analyses, including in patients with episodic or chronic migraine with prior prophylactic treatment failure and/or patients with a history of aura. Although the efficacy and tolerability profiles of erenumab remain to be determined in specific populations (for example, in patients with major cardiovascular disease), it is a promising candidate for alleviating the widespread personal, societal and economic burdens that are presently associated with migraine.

Notes

Acknowledgements

The manuscript was reviewed by: H.-C. Diener, Faculty of Medicine, University Duisburg-Essen, Essen, Germany; J. de Hoon, Center for Clinical Pharmacology, University Hospitals of Leuven, Leuven, Belgium. During the peer review process, Amgen Inc. and Novartis Pharmaceutical Corporation, the marketing-authorization holders of erenumab (Aimovig®), were also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

E.H. McCafferty and K.A. Lyseng-Williamson are employees of Adis, are responsible for the article content and declare no conflicts of interest.

References

  1. 1.
    Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.CrossRefGoogle Scholar
  2. 2.
    NICE (National Institute for Health and Care Excellence). Headaches in over 12s: diagnosis and management (CG150). London: NICE; 2012.Google Scholar
  3. 3.
    World Health Organization. Fact sheet: headache disorders. Geneva: World Health Organization; 2016.Google Scholar
  4. 4.
    Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–81.CrossRefGoogle Scholar
  5. 5.
    Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78(17):1337–45.CrossRefGoogle Scholar
  6. 6.
    Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Neurology. 2000;55(6):754–62.CrossRefGoogle Scholar
  7. 7.
    Steiner T, MacGregor E, Davies P. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication overuse headache, 3rd edition (1st revision). Hull: British Association for the Study of Headache; 2010.Google Scholar
  8. 8.
    Frampton JE, Silberstein S. OnabotulinumtoxinA: a review in the prevention of chronic migraine. Drugs. 2018;78(5):589–600.CrossRefGoogle Scholar
  9. 9.
    Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22–33.Google Scholar
  10. 10.
    Yaldo AZ, Wertz DA, Rupnow MF, et al. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting. Clin Ther. 2008;30(12):2452–60.CrossRefGoogle Scholar
  11. 11.
    Holland S, Fanning KM, Serrano D, et al. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. J Neurol Sci. 2013;326(1–2):10–7.CrossRefGoogle Scholar
  12. 12.
    Woolley JM, Bonafede MM, Maiese BA, et al. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache. 2017;57(9):1399–408.CrossRefGoogle Scholar
  13. 13.
    Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210.CrossRefGoogle Scholar
  14. 14.
    Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.CrossRefGoogle Scholar
  15. 15.
    Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014;28(5):389–99.CrossRefGoogle Scholar
  16. 16.
    Benarroch EE. CGRP sensory neuropeptide with multiple neurologic implications. Neurology. 2011;77(3):281–7.CrossRefGoogle Scholar
  17. 17.
    Buture A, Gooriah R, Nimeri R, et al. Current understanding on pain mechanism in migraine and cluster headache. Anesth Pain Med. 2016;6(3):1–8.CrossRefGoogle Scholar
  18. 18.
    Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.CrossRefGoogle Scholar
  19. 19.
    Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–7.CrossRefGoogle Scholar
  20. 20.
    Lassen L, Haderslev P, Jacobsen V, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61.CrossRefGoogle Scholar
  21. 21.
    Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179–86.CrossRefGoogle Scholar
  22. 22.
    Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533–52.CrossRefGoogle Scholar
  23. 23.
    Aimovig (erenumab): EU summary of product characteristics. Dublin: Novartis Europharm Limited; 2018. https://www.ema.europa.eu/documents/product-information/aimovig-epar-product-information_en.pdf. Accessed 11 Oct 2018.
  24. 24.
    Aimovig™ (erenumab-aoee) injection, for subcutaneous use: US prescribing information. Thousand Oaks: Amgen Inc.; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf. Accessed 11 Oct 2018.
  25. 25.
    Giamberardino MA, Affaitati G, Costantini R, et al. Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. J Pain Res. 2017;10:2751–60.CrossRefGoogle Scholar
  26. 26.
    Xu Y, Gabriel K, Wang Y, et al. A multicenter, open-label, pharmacokinetic drug interaction study of erenumab (AMG 334) and a combined oral contraceptive in healthy female subjects [abstract no. PS23]. Headache. 2017;57(Suppl 3):192–3.Google Scholar
  27. 27.
    de Hoon J, Van Hecken A, Vandermeulen C, et al. Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. Cephalalgia. 2018.  https://doi.org/10.1177/0333102418776017.Google Scholar
  28. 28.
    de Hoon J, Van Hecken A, Vandermeulen C, et al. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther. 2018;103(5):815–25.CrossRefGoogle Scholar
  29. 29.
    Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356(1):223–31.CrossRefGoogle Scholar
  30. 30.
    Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):382–90.CrossRefGoogle Scholar
  31. 31.
    Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–37.CrossRefGoogle Scholar
  32. 32.
    Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–32.CrossRefGoogle Scholar
  33. 33.
    Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018.  https://doi.org/10.1016/s0140-6736(18)32534-0.Google Scholar
  34. 34.
    Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–34.CrossRefGoogle Scholar
  35. 35.
    Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47–55.CrossRefGoogle Scholar
  36. 36.
    Silberstein S, Lenz R, Xu C. Therapeutic monoclonal antibodies: what headache specialists need to know. Headache. 2015;55(8):1171–82.CrossRefGoogle Scholar
  37. 37.
    Ashina M, Dodick D, Goadsby PJ, et al. Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study. Neurology. 2017;89(12):1237–43.CrossRefGoogle Scholar
  38. 38.
    Paemeleire K, Broessner G, Brandes J, et al. Efficacy of erenumab in subjects with episodic migraine with prior preventive treatment failure(s) [abstract no. O1]. J Headache Pain. 2017;18(Suppl 1):135–6.Google Scholar
  39. 39.
    Pascual J, Buse DC, Starling AJ, et al. Effect of erenumab on patient-reported outcomes in episodic migraine patients with prior prophylactic treatment failure: results from a post-hoc analysis of the STRIVE study [abstract no. PS49]. Headache. 2018;58(Suppl 2):179–80.Google Scholar
  40. 40.
    McAllister P, Gomez JP, McGill L, et al. Efficacy of erenumab for the treatment of patients with episodic migraine with aura [abstract no. P4.094]. Neurology. 2018;90(15 Suppl).Google Scholar
  41. 41.
    Tepper S, Broessner G, Buse D, et al. Efficacy of erenumab for the treatment of patients with episodic migraine with depression and/or anxiety [abstract no. P4.105]. Neurology. 2018;90(15 Suppl).Google Scholar
  42. 42.
    Pavlovic J, Paemeleire K, Gobel H, et al. Efficacy of erenumab in women with and without a history of menstrually-related migraine [abstract no. P4.096]. Neurology. 2018;90(15 Suppl).Google Scholar
  43. 43.
    Ashina M, Tepper S, Brandes JL, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;38(10):1611–21.CrossRefGoogle Scholar
  44. 44.
    Lanteri-Minet M, Buse DC, Starling AJ, et al. Patient-reported outcomes in chronic migraine patients with prior prophylactic treatment failure receiving placebo or erenumab: subgroup analysis of a pivotal randomized study [abstract no. PS36]. Headache. 2018;58(Suppl 2):170–1.Google Scholar
  45. 45.
    Diener HC, Ashina M, Brandes J, et al. Efficacy of erenumab for the treatment of patients with chronic migraine in presence of medication overuse [abstract no. PR1048]. Eur J Neurol. 2017;(Suppl 1):472.Google Scholar
  46. 46.
    Ashina M, Dodick D, Goadsby P, et al. Efficacy of erenumab for the treatment of patients with chronic migraine with and without aura [abstract no. S32.006]. Neurology. 2018;90(15 Suppl).Google Scholar
  47. 47.
    Assessment report: Aimovig. London: European Medicines Agency; 2018.Google Scholar
  48. 48.
    Winner P, Reuter U, Dodick D, et al. Erenumab safety among migraine patients using triptans or with cardiovascular (CV) risk factors [abstract no. P4.100]. Neurology. 2018;90(15 Suppl).Google Scholar
  49. 49.
    Tepper S, Pascual J, Reuter U, et al. Analysis of blood pressure following short-term and long-term treatment with erenumab [abstract no. P4.103]. Neurology. 2018;90(15 Suppl).Google Scholar
  50. 50.
    Vargas B, Starling A, Silberstein S, et al. Erenumab immunogenicity: a pooled analysis of phase 2 and phase 3 migraine prevention clinical trials [abstract no. P4.098]. Neurology. 2018;90(15 Suppl).Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Emma H. McCafferty
    • 1
    Email author
  • Katherine A. Lyseng-Williamson
    • 1
  1. 1.SpringerAucklandNew Zealand

Personalised recommendations